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Diagnosis and treatment strategies of thrombophilic risk factors
Trombofilik risk faktörleri, takip ve tedavi stratejileri
Osman Yokuş1, Özlem Şahin Balçık2, Murat Albayrak3
ÖZET
Trombofili,  hemostaz  mekanizmalarındaki  bozukluktan 
kaynaklanan ve tromboza eğilim oluşturan bir grup ka-
lıtsal ve kazanılmış durumun genel adı olarak tanımlan-
maktadır.  Tromboza  eğilimi  artırdığı  bilinen  kazanılmış 
risk faktörleri olarak santral venöz kataterler, sepsis, cer-
rahi, hiperlipidemi, konjestif kalp hastalığı, artmış lipopro-
tein a, yaşlılık, antifosfolipid sendrom, nefrotik sendrom, 
hiperviskozite, kronik miyeloproliferatif neoplazmlar, pa-
roksismal nokturnal hemoglobinüri, heparine bağlı trom-
bositopeni,  vaskülit,  immobilite,  obesite,  büyük  cerrahi 
girişim, travma, yanık, malignite, gebelik ve oral kontra-
septif kullanımı sayılabilir. Genç yaşta bilinen bir neden 
olmaksızın venöz tromboemboliye genetik yatkınlık, ka-
lıtsal trombofili olarak tanımlanmaktadır. Faktör V Leiden, 
protrombin  G20210A,  metilentetrahidrofolat  redüktaz 
gen mutasyonları, faktör VIII yüksekliği, protein C, pro-
tein S and antitrombin eksikliği parametrelerinin kalıtsal 
trombofili düşünülen hasta gruplarında araştırılması öne-
rilmektedir. Kalıtsal trombofilik etkenlerin seçilmiş hasta 
gruplarında  saptanmaları  tedavi  stratejileri  geliştirmede 
ve prognozda yol gösterici olmaktadır. Her toplum gene-
tik heterojenite nedeni ile kendi trombofilik risk havuzu-
nu belirlemelidir. Bu şekilde trombofilik risk faktörlerinin 
belirlenmesi gereksiz tetkik istenmesini engelleyecek ve 
maliyet-etkin bir yaklaşım geliştirilebilecektir. Klin Den Ar 
Derg 2010; 1(2): 125-133
Anahtar kelimeler: Trombofili, venöz tromboembolizm, 
Faktör V Leiden gen mutasyonu, Protrombin G20210A 
gen mutasyonu
ABSTRACT
Thrombophilia is defined as the general name for a group 
of genetic and acquired situations, arising from defects 
of  hemostasis  mechanism  and  generating  tendency  to 
thrombosis. Examples of the acquired risk factors that in-
crease the tendency to thrombosis are venous catheters, 
sepsis,  surgery,  hyperlipidemia,  congestive  heart  dis-
ease, increased lipoprotein a, old age, antiphospholipid 
syndrome,  nephrotic  syndrome,  hyperviscosity,  chronic 
myeloproliferative neoplasms, paroxysmal nocturnal he-
moglobinuria,  heparin  induced  thrombocytopenia,  vas-
culitis, immobility, obesity, major surgery, trauma, burns, 
malignancy,  pregnancy  and  oral  contraceptive  usage. 
Genetic tendency to venous thromboembolism in early 
ages, even without any known cause, is named as throm-
bophilia. Factor V Leiden, prothrombin G20210A, meth-
ylenetetrahydrofolate  reductase  gene  mutations,  factor 
VIII elevation, protein C, protein S and antithrombin de-
ficiency parameters are suggested for evaluation, in pa-
tient groups suspected of inherited thrombophilia. Detec-
tion of inherited thrombophilic factors in selected patient 
groups is a guide in developing treatment strategies and 
in establishing prognosis. Due to the genetic heterogene-
ities, each society should determine their thrombophilic 
risk pool. Thus, with the determination of the risk factors, 
unnecessary assessments will be prevented and a cost-
effective approach can be developed. J Clin Exp Invest 
2010; 1(2): 125-133
Key  words:  Thrombophilia,  venous  thromboembolism, 
Factor V Leiden gene mutation; Prothrombin G20210A 
gene mutation
INTRODUCTION
Today, one of the most common causes of diseases 
and deaths are arterial and venous thrombi. Venous 
thromboembolism (VTE) diseases are in the third 
line after atherosclerotic cardiac diseases and stroke 
among cardio-vascular diseases1. While the preva-
lence of venous thromboembolism in the adults is 
1/100.000 in younger ages and it increases to the 
rate of 1/100 in the older people. Frequently, VTE is 
observed in lower extremities. Occasionally, throm-
bosis may occur in other vascular localizations (i.e. Ö.Ş. Balçık et al. Thrombophilic risk factors 126
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upper extremity, mesentery, portal, retinal, cerebral, 
hepatic and renal veins and arteries). It has been 
reported that 30% of the VTE experienced patients 
died in the first 30 days2.
Thrombophilia is defined as the general name 
for a group of genetic and acquired situations, aris-
ing from defection of hemostasis mechanism and 
generating tendency for thrombosis. Examples of 
the acquired risk factors that increase the tendency 
to thrombosis are venous catheters, sepsis, surgery, 
hyperlipidemia, congestive heart disease, increased 
lipoprotein-a, old age, antiphospholipid syndrome 
(APS), nephrotic syndrome, hyperviscosity, myelo-
proliferative diseases, paroxysmal nocturnal hemo-
globinuria (PNH), heparin induced thrombocytope-
nia, vasculitis, immobility, obesity, major surgery, 
trauma,  burns,  malignancy,  pregnancy  and  oral 
contraceptive usage3,4. Genetic tendency to VTE in 
early ages, even without any known cause, is named 
as  thrombophilia.  Inherited  thrombophilic  defect 
should be considered in cases, like spontaneous and 
recurrent thrombosis in early ages, thromboembolic 
events in family anamnesis, development of mas-
sive thrombosis in atypical areas, recurrent abortus 
in pregnancy, skin necrosis following the anticoagu-
lant treatment. “Thrombophilia diagnosis” is made 
for  patients  who  had  recurrent  thrombosis  attack 
without any confirmed inherited thrombophilic fac-
tors or without diagnosis of APS5, 6.
In random patient groups with VTE, all of the 
thrombophilic  factors  of  thrombosis  generating 
a tendency to thrombosis were determined in one 
third of the cases and more than half of those were 
diagnosed  with  inherited  thrombophilia.  Risk  for 
thrombosis is also increasing, with the presence of 
combination of these defects.
Further investigation is suggested for some pa-
tient groups who developed clinical thrombosis, in 
the view of following parameters; Factor V Leiden 
(FVL),  prothrombin  G20210A  (PTG),  methyle-
netetrahydrofolate reductase (MTHFR) gene muta-
tions, elevated factor VIII (FVIII), Antiphospholip-
id antibodies (APA) [Anticardiolipin antibodies and 
Lupus anticoagulant] and deficiencies of protein C 
(PC), protein S (PS)and antithrombin (AT). In lit-
erature, most data is available for these parameters 
to be related with thrombosis. The most common 
causes of acquired and hereditary thrombophilia are 
summarized in Table 1.
Although, frequency of inherited thrombophilic 
factors vary  in  many societies or  patient groups, 
frequency of prothrombotic causes in societies be-
comes more clear, with the help of conducted stud-
ies.
Table 1. The most common causes of acquired and hereditary thrombophilia
Acquired Hereditary
Age FVL Mutation (Activated Protein C Resistance)
Immobilization PTG Mutation
Surgery MTHFR Gene Mutation 
Malignancy PC Deficiency
Pregnancy PS Deficiency
Oral Contraceptive Drugs AT Deficiency
Hormone Replacement Treatments Elevation of Factor VIII, Factor IX, Factor XI and Prothrombine
Antiphospholipid Antibodies (Anticardiolipin
antibodies and Lupus anticoagulant)
Chronic Myeloproliferative Neoplasms
FVL: Factor V Leiden G1691A mutation; PTG: Prothrombin G20210A mutation; MTHFR: 5,10-methylenetetrahydrofo-
late reductase mutation; PC: Protein C; PS: Protein S; AT: AntithrombinÖ.Ş. Balçık et al. Thrombophilic risk factors 127
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1. Inherited thrombophilia and Thromboembolism
a.  FVL  mutation  (Activated  protein  C  resistance 
(APC-R): APC- active form of endogenous antico-
agulant protein PC destroys and deactivates the ac-
tive forms of factor V and FVIII. In 1993, APC-R 
was detected in some individuals with clinic hyper-
coagulability and this is thought to be inherited phe-
nomena  with  autosomal  dominant  feature. After-
wards, the molecular defect accounting for APC-R, 
is found by Leiden as a single point mutation of FV 
gene. As a result of this mutation, arginine and glu-
tamine replacement occurs in protein fragmentation 
point and active FV becomes partially resistant for 
break up by APC. This genetic defect accounts for 
90% of the inherited thrombophilia cases and APC-
resistance. 
FVL  frequency  varies  in  different  ethnical 
groups. Even though the carrier rate of Caucasians 
is between 3–5%, it is rarer in Asian and African 
populations.  Most  common  clinical  symptom  of 
FVL  is  deep  vein  thrombosis  (DVT).  Acquired 
APC-R may be observed in pregnancy, estrogen us-
age, older age and APS and FVIII elevation. In the 
case control studies, DVT risk is showed to be in-
creased 5–10 folds in FVL heterozygote cases and 
80% in homozygote cases. Consequently, 50% of 
thromboembolic  cases  with  undetermined  predis-
posing factors can be explained with FVL (APC-R) 
mutations. APC-R  is  one  of  the  most  important 
causes of hypercoagulability7.
a. PTG mutation: Prothrombin is the precursor 
molecule of thrombin, activating FV and FVIII, and 
converts fibrinogen to fibrin. As a result of the mu-
tation of the allele in 20210A nucleotide position of 
the prothrombin gene, prothrombin level increases 
and  tendency  to  venous  thrombosis  occurs.  PTG 
gene allele is confirmed as one of the most common 
genetic factors that related with venous thrombosis. 
Its  prevalence  is  approximately  5-6%  in  un-
selected  DVT  patients,  0.7-3%  in  control  group, 
18% in patients with family history of thrombosis. 
Heterozygote PTG careers have 2-5 folds increased 
risk of thrombosis comparing with the unaffected 
control group. DVT recurrence risk increases 2-4 
folds. VTE risk is increased in patients with PC, PS, 
AT deficiency and FVL mutation more than the pa-
tients with PTG mutation8.
b.  MTHFR  gene  mutation  and  Hyperhomo-
cysteinemia:  Thermolabile  homozygote  mutated 
forms of MTHFR enzyme is a genetic abnormality 
which is more common and which causes moderate 
hyperhomocysteinemia. It is suggested that in vitro 
homocysteine antagonizes the synthesis and func-
tion of nitric oxide and causes vascular endothe-
lial  damage  and  develops  a  thrombogenic  effect 
through many different ways. There are also evi-
dences proving that, moderate hyperhomocysteine-
mia may cause coroner artery disease and occlusive 
arterial disease and particularly with the presence of 
other thrombophilic situations, it increases the risk 
of VTE to 2.5 folds. The increased risk of VTE with 
the elevation of homocysteine is more frequent in 
women than men and the risk becomes higher with 
the elder age. Hyperhomocysteinemia is the throm-
bophilic factor which is easiest to treat. The asso-
ciation between thermolabile MTHFR gene variant 
and thrombosis is not independent and the risk of 
thrombosis increases proportionally with the eleva-
tion of homocysteine levels which is determined by 
complex relationship between genetic and environ-
mental factors. It increases the risk of thrombosis 
when combined with FVL mutations. Patients with 
these two defects concurrently, the risk of VTE is 
increased 10 folds comparing with normal control 
group; however, the risk is moderate in people with 
one single defect. The two most common heritable 
polymorphisms are C677T and 1298 position poly-
morphisms of MTHFR gene. In Caucasians, preva-
lence of C677T polymorphism is 6-12%1.
c. Protein C, Protein S and Antithrombin De-
ficiencies: Deficiency of endogenous anticoagulant 
proteins PC, PS and AT is the first determined ge-
netic cause of thrombophilia. In unselected patients 
among those admitted with DVT, the frequency of 
these 3 defects is approximately 7%. Usually these 
defects  are  inherited  in  an  autosomal  dominant 
condition and homozygote cases generally die in-
trauterine or shortly after birth. Clinic expression 
of heterozygote cases varies with clinic phenotype 
expressions and presence of other clinic and genetic 
abnormalities which cause tendency for thrombo-
sis1, 8.
Protein C: Synthesized in the liver depending 
on vitamin K (K-vit). PC transforms to APC with 
the combination of thrombomoduline and throm-
bin in the endothelial surface. APC inactivates FVa Ö.Ş. Balçık et al. Thrombophilic risk factors 128
J Clin Exp Invest   www.clinexpinvest.org   Vol 1, No 2, September 2010
and FVIIIa with contribution of  PS. There are two 
types of defects; Type I (quantitative) and Type II 
(qualitative). Prevalence of PC defect is determined 
in general population in a rate of 0.2 – 0.3% and 
in patients experienced one thrombosis attack in a 
rate 3%. This rate decreases in liver disease, K-vit 
deficiency, oral anticoagulant usage and disseminat-
ing intravascular coagulation (DIC). In the state of 
acute thrombosis, it may decrease due to the con-
sumption; therefore the results are not reliable. An-
nual thromboembolism incidence was calculated in 
a rate of 2.5% in patients with PC defect, who have 
not experienced any thrombi, but there is a family 
history. VTE development is also seen in 50% of 
patients around the age of 45, with a family history 
of heterozygote PC deficiency.
Protein S: It is mostly synthesized in the liver, 
depending on vitamin-K. It is the co-factor of PC. 
Active part is the free form. In the FVIII elevation 
and FVL presence, false decrease may be seen. PS 
may be decreased in following situations; inflamma-
tion, pregnancy, presence of APA and situations that 
cause decreased PS. Prevalence of PS deficiency is 
approximately 1-2%. Family individuals of patients 
with PS deficiency have increased risk for throm-
boembolism. Thrombosis is in idiopathic, juvenile 
and recurrent characteristics.
Antithrombin is an endogenous anti-coagulant 
that  inhibits  the  biological  activities  of  thrombin 
and other coagulation cascade, binding their active 
coagulation factor. Two types of deficiency are de-
scribed; Type I (quantitative) and Type II (qualita-
tive). AT affects with inhibition of factor IX, X, XI, 
XII. Its effect is 1000 fold more than heparin’s ef-
fect and if combined with heparin sulphate, this ef-
fect increases. Frequency of deficiency is 0.02% in 
normal population and this rate is approximately 1% 
in cases with thrombosis. Homozygote deficiency is 
rare and not compatible with life. Acquired AT defi-
ciency may be found in cases such as liver disease, 
nephritic syndrome, DIC, L-asparaginase treatment, 
pregnancy and heparin usage, although it may de-
crease in acute consumption.
d. Elevation of coagulation factor and throm-
bophilia: Factor VIII (FVIII), factor IX (FIX), fac-
tor XI (FXI) and prothrombine is reported as the 
independent risk factors for VTE9. In the case of 
idiopathic recurrent VTE, measurements of FVIII 
level are suggested, and if high levels are deter-
mined, long-term anticoagulant administration may 
be considered10, 11.
2. Reasons of acquired thrombophilia
One of the most common acquired thrombophilia 
factors is malignity. Cancer patients are in a hy-
percoagulable state, even though they do not have 
thrombosis. Pathogenesis of thrombosis in cancer 
is multifactorial. Two main mechanisms of devel-
opment of prothrombic thrombosis are; interacting 
capacities of tumor cells with homeostatic mecha-
nisms and anti-tumor treatment.
a. Antiphospholipid antibodies (APA): It is one 
of the common acquired thrombophilic factors. APS 
is  thrombophilic,  immunologic  syndrome,  deriv-
ing from heterogeneous auto-antibodies which de-
veloped against biological membranes that mainly 
originate from phospho-lipid components. Clinical 
symptoms of this syndrome are arterial and venous 
thrombosis, recurrent abortus and thrombocytope-
nia,  and  serologic  findings  are  IgG  or  IgM  anti-
cardiolipine antibodies (ACA) or presence of Lupus 
anticoagulant (LA). At least one serologic finding 
should be present with a clinical finding in order to 
make the diagnosis12. 
Frequency of ACA is between 1-9% in general 
population. Myocardial infarction and other arterial 
vascular areas are proven to be independent factors 
for thrombosis and recurrence of thrombosis. APS 
may be caused by primer or secondary (systemic 
lupus  erythematosus,  malignancy,  infections,  and 
drugs) factors. While its frequency in general popu-
lation is 1-5%, this rate is 12-30% for ACA and it 
reaches to 15-44% for LA.
In  the  presence  of  recurrence  of  thrombotic 
events, life-treating thrombotic events or high titrate 
AFA,  long-term  or  lifelong  prophylaxis  may  be 
needed13, 14.
b. Oral Contraceptive, Hormone Replacement 
Treatments  and  Thrombophilia:  Women,  taking 
hormone  replacement  treatment  (HRT)  have  2-5 
times increased risk of VTE comparing with the 
others. Patients taking higher dose or single estro-
gen containing drugs have increased risk in regards 
to the thromboembolic events compared to lower 
dose estrogen or combined therapy (estrogen plus 
progesterone)  prescribed  patients.  Thrombophilia 
increases the risk of VTE particularly with the pres-
ence of FVL and HRT. Overweighing and old age Ö.Ş. Balçık et al. Thrombophilic risk factors 129
J Clin Exp Invest   www.clinexpinvest.org   Vol 1, No 2, September 2010
are additional factors that increase the risk. Before 
prescribing oral contraceptive drugs, thrombophilia 
screening tests should be performed to the individu-
als a history of VTE15.
c. Pregnancy and the risk of thrombosis: The 
risk of developing early, recurrent and late abortions, 
pre-eclampsia, abruptio placentae and intrauterine 
growth retardation are increased in thrombophilic 
defective patients. Most increased thrombosis risk 
in pregnancy was found to be accompanying with 
FVL mutations. Particularly, pregnant patients with 
homozygote form of this mutation, have 34-folds-
increased risk of VTE comparing with the normal 
pregnancies15.  Thrombophilia  screening  is  sug-
gested for individuals who have a history of VTE in 
pregnancy, personal and family history16.
d. Surgery and Thrombophilia: Post-operative 
VTE,  pulmonary  embolism  (PE)  and  FVL  were 
significantly related to PTG mutations and FVIII 
elevation. AT deficiency, MTHFR and hyperhomo-
cysteinemia are not found to be related with VTE 
risk. Screening of the sub-groups with the history of 
VTE among who have the possibility for thrombo-
philia is much more cost-effective than screening of 
the general population17.
3. To whom and when the thrombophilia screen-
ing test should be required? Thrombophilia screen-
ing aims to determine the patient who may benefit 
from long-term anticoagulation treatment and needs 
for prophylactics in risky status. In a study, a cost 
effectiveness analyze was assessed in two groups of 
patients with a family history of inherited thrombo-
philia who were evaluated before surgery, pregnan-
cy, birth and OKS vs. those who were not evaluated. 
It was emphasized that cost would be decreased with 
the thrombophilia screening tests before the risky 
situation, in such selective patient sub-groups with 
personal and family history of thromboembolism18.
The individuals, who had a previous spontane-
ous VTE attacks or recurrent thrombotic attacks be-
fore age 50 and who had a family history of throm-
bosis at close relatives, are suggested to be evalu-
ated for PC, PS and AT deficiency, APC-R, PTG 
mutation, APA and plasma homocysteine levels19,20.
In  patients  with  VTE,  routine  thrombophilia 
test should be performed when an abnormality is 
observed, if duration and type of anticoagulant treat-
ment will be changed. In our knowledge, there is no 
difference in the way of anticoagulation between 
the patients with or without thrombophilic factors, 
other than APS21. Laboratory analyses and the fre-
quency of the disease were investigated in patients 
with spontaneous development of thrombosis and 
in the control group in sporadic areas, and inher-
ited thrombophilia was found to be more frequent 
in  thrombotic  cases.  Thrombophilia  screening  is 
suggested for patients with spontaneous thrombosis 
(except central retinal vein thrombosis) 22.
Natural  anticoagulant  levels  decrease  due  to 
consumption in acute thrombosis. Heparin - depen-
dent AT, warfarine - bounded PC and PS decrease. 
However, genetic tests are not affected by the treat-
ments. Treatment is not effected by any diagnosed 
defect during acute thrombosis. Phenotypical test 
should be performed after 3 months of acute throm-
botic event and minimum two weeks after the dis-
continuation date for oral anticoagulant treatment. 
If  anticoagulant treatment cannot be discontinued, 
warfarine should be discontinued and switched to 
heparin. After 10 days of switch, PC ad PS can be 
performed.
4. Thrombophilia and tThrombosis presentation
a. Ischemic Stroke (IS): Generally, IS is a situation 
that occurs depending on arterial disease (carotid 
stenosis, etc) or cardiac disease (atrial fibrillation, 
etc). Studies on the role of inherited thrombophilia 
shows different results about presence of thrombo-
philic  factors,  different  vessel  involvement  areas 
and ethnic group differences in the etiology of ce-
rebral artery and venous thrombosis (CAT, CVT). 
It was reported that IS is responsible for 1-4% of 
hypercoagulable events but inherited thrombophilia 
have the greatest portion of inheritance in younger 
sub-group of IS patients. In some studies, while the 
role of inherited thrombophilia in IS etiology cannot 
be determined, PC deficiency, FVL and PTG gene 
mutation are found more frequent in SVT 23, 24.
Presence of MTHFR gene mutation and eleva-
tion of homocysteine levels are found to be related 
with increased SVT risk, particularly accomplish-
ment with low folate level and in populations with 
lower socio-economical status. Thrombophilic tests 
are recommended for young IS patients that etiol-
ogy cannot be explained, particularly if they have 
personal and family history of thrombosis.Ö.Ş. Balçık et al. Thrombophilic risk factors 130
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b.  Retinal  vessel  thrombosis:  Central  retinal 
vein and retinal artery thrombosis (retinal vascular 
thrombosis: RVT), are the most common vascular 
diseases  of  the  eye  and  general  cause  of  serious 
vision loss. Usual causes of retinal embolism are 
stasis, increase in viscosity and thrombus. Relation-
ship between thrombophilic risk factors and RVT is 
needed to be clarified. Some of risk factors such as; 
arterial hypertension (HT), diabetes mellitus (DM) 
and atherosclerosis are important in the etiology. 
Hyperhomocysteinemia,  MTHFR  gene  polymor-
phism and APS result in central RVT, and as a cause, 
hyperfibrinolysis is a major factor. In some studies, 
however, thrombophilia frequency is demonstrated 
to be similar with control group, which means it is 
not a risk factor. Thrombophilic factors cannot be 
defined to be a prominent factor for RVT25,26.
c. Pulmonary embolism (PE): PE is a multi-fac-
torial etiologic clinic manifestation which develops 
secondary to DVT, usually, at the lower extremities. 
6% of PE results in death. Prevalence varies with 
age  and  ethnic  group.  Inherited  thrombophilia  is 
determined as a cause of non-predisposal factor of 
35% cases.
Acquired risk factors for PE development are 
inherited factors, FVL, PTG, PC, PS, AT deficien-
cies as well as acquired risk factors such as, estro-
gen  replacement,  cancer,  cardiovascular  disease, 
surgery, trauma, immobility, central venous catheter 
usage. Risk increases with the combination of ge-
netic and acquired factors27.
d. Upper extremity vessel thrombosis (UEVT): 
It is a rare thrombotic event. Generally, thrombo-
sis develops due to the acquired predisposing fac-
tors, i.e; catheter, malignity, exercises. The role of 
thrombophilia in pathogenesis is not well known28. 
In  a  study,  evaluating  the  acquired  and  inherited 
thrombophilia factors that have a role in spontane-
ous UEVT etiology, less than 61.3% of cases were 
diagnosed with a coagulation abnormality29. APA is 
determined as the most common factor.
e.  Abdominal  vessel  thrombosis:  Abdominal 
vessel  thrombosis  inventory  is  frequently  related 
with  congenital  and  acquired  thrombophilia  in 
adults, and related clinic presentations may vary. 
Portal  vein  thrombosis  (PVT),  Budd-Chiari  Syn-
drome, mesenteric vein thrombosis can be accom-
plished  with  acute  abdominal  syndrome,  chronic 
hepatomegaly  and  even  with  asymptomatic  pan-
cytopenia. Also these manifestations may cause to 
some complications i.e.; esophageal varices, portal 
gastropathy,  ascite,  serious  hypersplenism,  liver 
failure  that  requires  transplantation.  In  complica-
tions  of  intraabdominal  vessel  thrombosis,  treat-
ment strategies are not different from hypertension 
treatment however prognosis is better30.
f.  Placental  vascular  thrombosis  (Habitual 
abortus): Some changes in coagulation system oc-
cur in order to prevent the bleeding complications 
in normal pregnancies. The risk of thrombosis is in-
creased in pregnant. Thrombophilia screening tests 
should be performed in pregnancy or puerperium-
related VTE, in 2 or more abortus and in fetal intra-
uterine death cases, occurring in 1st or 2nd trimes-
ter. Routine thrombophilia screening is suggested in 
pregnancy31. VTE in pregnancy is one of the ma-
jor factors that increase the maternal mortality and 
morbidity. Most of these deaths can be prevented 
with optimal prophylaxis and treatment strategies. 
VTE risk is elevated 3 to 15 fold in pregnancy. Re-
currence risk is increased 3.5 folds in patients who 
previously experienced a VTE. Acquired thrombo-
philic risk factor was detected in 2/3 of pregnancies 
and inherited thrombophilic risk factor was detected 
30-50%  of  pregnancies  among  who  experienced 
VTE.
g. Arterial thrombosis and thrombophilia: Al-
though in small studies with children and young 
women, it was suggested that thrombophilia has a 
role in arterial thrombosis, it could not confirmed 
with large-scaled studies. Presence of FVL and PTG 
mutations may increase the risk. Through the inves-
tigation of inherited thrombophilia factors in young 
patients  who  experienced  thrombosis  in  arterial 
fields, without presence of conventional risk factors 
(i.e.; smoking, HT, DM), thrombophilia frequency 
has shown a mild increase32.
5. Treatment and prophylaxis
Annual incidence of recurrence in VTE is 5-10% 
that is assessed as a chronic disorder. Patients with 
VTE should take an anticoagulant treatment for at 
least 3 months. Treatment duration should be de-
termined with the assessments of response to treat-
ment and possible complications. Patients with high 
risk of recurrence should be determined and con-
sidered for long-term treatment. Patients with AT 
deficiency, LA positivity, FVL (homozygote), pres-Ö.Ş. Balçık et al. Thrombophilic risk factors 131
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ence of combined inherited defect or more than one 
thrombosis episodes are predicted to have high risk 
of recurrence.
Primarily,  low-molecular-weight  heparin 
(LMWH) or heparin is initiated with warfarin and 
treatment is continued for 5 days. When the inter-
national normalized ratio (INR), range is between 2 
and 3 for 2 subsequent days, warfarin is discontin-
ued (if not pregnant).
Generally after the first attack, 6 months treat-
ment  is  prescribed,  however,  if  the  distal  vein 
thrombosis is present and triggering event is tempo-
rary, 3 months of warfarin treatment is prescribed. 
If thrombosis reoccurs at the end of treatment, anti-
coagulation is initiated as the same way. Treatment 
is maintained with an INR range of 2-3. If recur-
rence occurs, dose escalation is made to INR 3-4 
range. For the treatment of patients with congenital 
AT deficiency, AT concentrates can be given with 
intravenous heparin treatment33, 34.
a. Treatment and prophylaxis of pregnant with 
thrombophilia: Pregnant women with PS deficien-
cy, heterozygote FVL and PTG mutations have low 
risk and thromboprophylaxis is not recommended. 
However, thromboprophylaxis is suggested for in-
herited thrombophilic pregnant who develops com-
plications, such as recurrent abortions, intrauterine 
fetal death and severe preeclampsia, in case of a 
4-hours flight trip or additional thrombotic risk fac-
tor. Pregnant with PC and AT deficiency, homozy-
gote mutations of FVL and PTG and other com-
bined thrombophilic defects, has moderate throm-
bosis risk. Thrombophylaxis is suggested for these 
patients either in gestation or in puerperant periods. 
Cumarin derivations are not safe due to embriopa-
thy and fetal bleeding risk.
LMWH’s  are  safer  comparing  with  unfrac-
tioned heparin. If VTE is suspected in pregnant, an-
ticoagulant treatment should be continued if there is 
no contraindication, until VTE absence is showed. 
Heparin is used in pregnant with prosthetic heart 
valves35.
b. Prophylaxis in surgery: Prophylaxis is not 
necessary for patients under the age of forty, if no 
additional risk factor is present and anesthesia dura-
tion is below 30 minutes.
Risk level is moderate in patients over the age 
of forty and anesthesia duration over 30 minutes, 
starting from the 12 hours prior to the surgery; low 
dose standard heparin or one dose LMWH is sug-
gested. Patients undergoing to major surgery and 
aged over 40 with the additional risk factors, will be 
are accepted in the high risk group and prophylaxis 
is suggested during 7-10 days. 
c. Prophylaxis in malignancies: Results were 
published indicating that DMWH treatment is more 
effective than warfarin in case of malignancy com-
plications with thrombosis36.
CONCLUSION
Thromboembolism is a clinic entity that is common 
in adults and its etiology is generally multifacto-
rial. There are increasing numbers of publications, 
showing that the roles of inherited defects are im-
portant as much as acquired factors in the etiology 
of thrombosis in adults37. It is well known that fre-
quency of defects, which are assessed in thrombo-
philia screening, varies in different populations and 
ethnic groups even in different geographical regions. 
With proved thrombophilia factors; PC, PS, AT de-
ficiency, FVL mutation, APC-R, PTG and MTHFR 
mutation, FVIII elevation, tests for ACA and LA, 
that may affect the dose and duration of treatment, 
should be added to inherited thrombophilia screen-
ing list.
Since  1/3  of  thrombophilia  cases  are  deter-
mined with combined thrombophilic defects, it is 
suggested that after detection of one positive factor, 
tests should be continued with screening of at least 
3 or 5 common defects. Furthermore, combined de-
fects have critical importance in order to decide for 
duration and concentration of treatment. Treatment 
strategy is unclear, however long-term anticoagu-
lant treatment is recommended in the presence of 
APS.  Thrombophilic  treatment  recommendations 
should  be  given  in  consideration  of  thrombosis 
which may have acquired or inherited etiological 
origin in vein or artery, with temporary or perma-
nent characteristics. The risk for recurrence after 5 
years of thrombosis attack is 24% and following 8 
years, it is approximately 30%. Long-term antico-
agulation may be considered in such cases of two 
or more spontaneous thrombosis attack or spontane-
ous thrombosis at one of the life-threading regions 
(cerebral, mesentery, almost fatal PE), spontaneous 
thrombosis+APS combination, AT deficiency or de-
fect of more than one genetic allele (homozygote Ö.Ş. Balçık et al. Thrombophilic risk factors 132
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FVL, more than one heterozygote combine defects) 
38.
Training of patients for symptoms and clinical 
symptoms of thrombosis and disease ID cards for 
patients is suggested.
Treatment strategies are not completely identi-
fied for thrombosis of inherited thrombophilic cas-
es. Due to the risk of serious bleeding complication, 
fibrinolytic treatment is not widely used. Different 
treatment strategies should be decided with the con-
sideration of patients’ clinic situation and frequency 
of thrombosis.
In  brief;  determination  of    inherited  throm-
bophilic factors in selected patient groups will be 
guide for development of treatment strategies and 
prognosis. Due to the genetic heterogeneities, each 
society should determine their thrombophilic risk 
pool. Thus, with the determination of risk factors, 
unnecessary assessments will be avoided and a cost-
effective approach will be developed.
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